Latest News

AJ201 Demonstrates Promising Phase 1/2 Results in Spinal and Bulbar Muscular Atrophy
AJ201 Demonstrates Promising Phase 1/2 Results in Spinal and Bulbar Muscular Atrophy

June 4th 2025

AJ201 shows promising safety and efficacy in treating spinal and bulbar muscular atrophy, marking a potential breakthrough for patients.

Evaluating Risk: Clarifying the Safety Data Behind Efgartigimod
Evaluating Risk: Clarifying the Safety Data Behind Efgartigimod

June 4th 2025

Mahsa Ghajarzadeh, MD, PhD  (Credit: LinkedIn)
Meta-Analysis Reveals Cognitive Behavioral Therapy Ineffective for MS-Related Fatigue

June 3rd 2025

Real-World Safety of Cladribine Matches Clinical Trial Development
Real-World Safety of Cladribine Matches Clinical Trial Development

June 3rd 2025

OPTIMUM Phase 3 Extension Further Highlights Sustained Efficacy, Safety of Ponesimod
OPTIMUM Phase 3 Extension Further Highlights Sustained Efficacy, Safety of Ponesimod

June 3rd 2025

Coverage of PNS 2025

Get direct access to interviews with experts, straight from the conference floor in Vienna, as well as the latest data and clinical news updates.

PNS 2025

Conference Coverage

View All
Ahmed Abdelhak, MD
Emerging Biomarkers for Monitoring Remyelination in Multiple Sclerosis: Ahmed Abdelhak, MD

June 4th 2025

Evaluating Risk: Clarifying the Safety Data Behind Efgartigimod
Evaluating Risk: Clarifying the Safety Data Behind Efgartigimod

June 4th 2025

Smathorn Thakolwiboon, MD
A Case-Based Overview of Treatment Strategies for Relapse Prevention in MOGAD: Smathorn Thakolwiboon, MD

June 4th 2025

NeuroVoices: Kathy Zackowski, PhD, OTR, on Promoting Psychosocial Wellness Research in MS Care
NeuroVoices: Kathy Zackowski, PhD, OTR, on Promoting Psychosocial Wellness Research in MS Care

June 4th 2025

Video Series
Video Interviews
Podcasts

Most Recent

© 2025 MJH Life Sciences

All rights reserved.